Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement

por Leshem, Y.A., Bissonnette, R., Paul, C., Silverberg, J.I., Irvine, A.D., Paller, A.S., Cork, M.J., Guttman‐Yassky, E.
Publicado 2019

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes

por Cork, M.J., McMichael, A., Teng, J., Valdez, H., Rojo, R., Chan, G., Zhang, F., Myers, D.E., DiBonaventura, M.
Publicado 2021

Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK

por O’Kane, D, Davis, L, Ardern-Jones, M, Laws, P, Shaw, L, Cork, M, Velangi, S, Cooper, HL, Hudson, R, Smith, AB, Rout, R
Publicado 2021

Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa stud...

por Cork, M.J., Thaçi, D., Eichenfield, L.F., Arkwright, P.D., Sun, X., Chen, Z., Akinlade, B., Boklage, S., Guillemin, I., Kosloski, M.P., Kamal, M.A., O’Malley, J.T., Patel, N., Graham, N.M.H., Bansal, A.
Publicado 2020

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

por Paller, A.S., Siegfried, E.C., Simpson, E.L., Cork, M.J., Lockshin, B., Kosloski, M.P., Kamal, M.A., Davis, J.D., Sun, X., Pirozzi, G., Graham, N.M.H., Gadkari, A., Eckert, L., Ruddy, M., Bansal, A.
Publicado 2020

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion

por Thyssen, J.P., de Bruin‐Weller, M.S., Paller, A.S., Leshem, Y.A., Vestergaard, C., Deleuran, M., Drucker, A.M., Foelster‐Holst, R., Traidl‐Hoffmann, C., Eyerich, K., Taieb, A., Su, J.C., Bieber, T., Cork, M.J., Eichenfield, L.F., Guttman‐Yassky, E., Wollenberg, A.
Publicado 2019

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension

por Cork, M.J., Thaçi, D., Eichenfield, L.F., Arkwright, P.D., Hultsch, T., Davis, J.D., Zhang, Y., Zhu, X., Chen, Z., Li, M., Ardeleanu, M., Teper, A., Akinlade, B., Gadkari, A., Eckert, L., Kamal, M.A., Ruddy, M., Graham, N.M.H., Pirozzi, G., Stahl, N., DiCioccio, A.T., Bansal, A.
Publicado 2019

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)...

por Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J.‐P., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., Lesiak, A., Kircik, L., Cho, S.H., Herranz, P., Cork, M.J., Peris, K., Steffensen, L.A., Bang, B., Kuznetsova, A., Jensen, T.N., Østerdal, M.L., Simpson, E.L.
Publicado 2020

Conjunctivitis in dupilumab clinical trials

por Akinlade, B., Guttman‐Yassky, E., de Bruin‐Weller, M., Simpson, E.L., Blauvelt, A., Cork, M.J., Prens, E., Asbell, P., Akpek, E., Corren, J., Bachert, C., Hirano, I., Weyne, J., Korotzer, A., Chen, Z., Hultsch, T., Zhu, X., Davis, J.D., Mannent, L., Hamilton, J.D., Teper, A., Staudinger, H., Rizova, E., Pirozzi, G., Graham, N.M.H., Shumel, B., Ardeleanu, M., Wollenberg, A.
Publicado 2019